MedPath

浙江尖峰药业有限公司

Ownership
-
Established
1998-12-31
Employees
-
Market Cap
-
Website
www.zjjfyy.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

116

NMPA:116

Drug Approvals

Roxadustat Capsules

Product Name
罗沙司他胶囊
Approval Number
国药准字H20253546
Approval Date
Mar 4, 2025
NMPA

Roxadustat Capsules

Product Name
罗沙司他胶囊
Approval Number
国药准字H20253545
Approval Date
Mar 4, 2025
NMPA

Diquafosol Sodium Eye Drops

Product Name
地夸磷索钠滴眼液
Approval Number
国药准字H20249603
Approval Date
Dec 1, 2024
NMPA

Olopatadine Hydrochloride Eye Drops

Product Name
盐酸奥洛他定滴眼液
Approval Number
国药准字H20247155
Approval Date
Sep 29, 2024
NMPA

Oseltamivir Phosphate Capsules

Product Name
磷酸奥司他韦胶囊
Approval Number
国药准字H20244298
Approval Date
Aug 28, 2024
NMPA

Tafluprost Eye Drops

Product Name
他氟前列素滴眼液
Approval Number
国药准字H20243590
Approval Date
Apr 24, 2024
NMPA

Olopatadine Hydrochloride Eye Drops

Product Name
盐酸奥洛他定滴眼液
Approval Number
国药准字H20193095
Approval Date
Nov 8, 2023
NMPA

Moxifloxacin Hydrochloride Eye Drops

Product Name
盐酸莫西沙星滴眼液
Approval Number
国药准字H20234300
Approval Date
Oct 18, 2023
NMPA

Moxifloxacin Hydrochloride Eye Drops

Product Name
盐酸莫西沙星滴眼液
Approval Number
国药准字H20234301
Approval Date
Oct 18, 2023
NMPA

Lenvatinib Mesilate Capsules

Product Name
甲磺酸仑伐替尼胶囊
Approval Number
国药准字H20234192
Approval Date
Sep 28, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.